Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06928246 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis

Study acronym: AD
StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment closed, study ongoing Eligibility criteria expanded, about 26 words · Secondary endpoints: details revised at 2 of 2 entries · Site details revised at 2 of 2 sites · 1 more Show 4 more changesShow less
    • Eligibility criteria expanded, about 26 words
    • Secondary endpoints: details revised at 2 of 2 entries
    • Site details revised at 2 of 2 sites
    • Publications: details revised at 1 of 2 entries
  2. Re-verified, no change to tracked fieldsv5
  3. Primary completion date: Dec 15, 2025 to Dec 15, 2026 Completion date: Jan 2026 to Jan 2027v4 Show 1 more changeShow less
    • Completion date: Jan 2026 to Jan 2027
  4. Trial status: Not Yet Recruiting to Recruiting Study sites: 1 to 2 · Primary completion date: Dec 2025 to Dec 15, 2025 · Start date changed from estimate of Jul 1, 2025 to Jul 17, 2025v3 Show 3 more changesShow less
    • Study sites: 1 to 2
    • Primary completion date: Dec 2025 to Dec 15, 2025
    • Start date changed from estimate of Jul 1, 2025 to Jul 17, 2025
  5. Site contact updated Study description expanded, about 2 wordsv2 Show 1 more changeShow less
    • Study description expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to understand cellular and molecular interactions in the skin of participants with mild-to-moderate AD, and how botulinum toxin alters these interactions.
Trial Details
NCT Number NCT06928246
Lead Sponsor Daniel Kaplan
Collaborators: Almirall, S.A.
Conditions Atopic Dermatitis (AD)
Enrollment 8 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov